Published in Lancet on April 11, 1998
Safety and Efficacy Study of Intravenous Immunoglobulin to Treat Japanese Encephalitis | NCT01856205
Origin and evolution of Japanese encephalitis virus in southeast Asia. J Virol (2003) 3.92
Japanese encephalitis. J Neurol Neurosurg Psychiatry (2000) 2.76
Acute flaccid paralysis and West Nile virus infection. Emerg Infect Dis (2003) 2.34
Flavivirus infection activates the XBP1 pathway of the unfolded protein response to cope with endoplasmic reticulum stress. J Virol (2006) 2.02
Japanese encephalitis-a pathological and clinical perspective. PLoS Negl Trop Dis (2009) 1.82
Antiviral effects of an iminosugar derivative on flavivirus infections. J Virol (2002) 1.80
Ecological niche modeling and land cover risk areas for rift valley fever vector, culex tritaeniorhynchus giles in Jazan, Saudi Arabia. PLoS One (2013) 1.45
A preliminary randomized double blind placebo-controlled trial of intravenous immunoglobulin for Japanese encephalitis in Nepal. PLoS One (2015) 1.44
A cohort study to assess the new WHO Japanese encephalitis surveillance standards. Bull World Health Organ (2008) 1.39
Measuring the burden of arboviral diseases: the spectrum of morbidity and mortality from four prevalent infections. Popul Health Metr (2011) 1.37
Arboviral encephalitides: transmission, emergence, and pathogenesis. J Neuroimmune Pharmacol (2010) 1.24
An evaluation of the usefulness of neuroimaging for the diagnosis of Japanese encephalitis. J Neurol (2009) 1.14
A hospital-based surveillance for Japanese encephalitis in Bali, Indonesia. BMC Med (2006) 1.11
The inflammatory cytokine, interleukin-1 beta, mediates loss of astroglial glutamate transport and drives excitotoxic motor neuron injury in the spinal cord during acute viral encephalomyelitis. J Neurochem (2008) 1.10
Evidence and rationale for the World Health Organization recommended standards for Japanese encephalitis surveillance. BMC Infect Dis (2009) 1.03
Emerging arboviral encephalitis. Newsworthy in the West but much more common in the East. BMJ (2000) 1.02
Japanese viral encephalitis. Postgrad Med J (2002) 0.98
A prospective assessment of the accuracy of commercial IgM ELISAs in diagnosis of Japanese encephalitis virus infections in patients with suspected central nervous system infections in Laos. Am J Trop Med Hyg (2012) 0.93
Japanese encephalitis: the virus and vaccines. Hum Vaccin Immunother (2013) 0.93
Pathogenesis of Japanese encephalitis virus infection in a golden hamster model and evaluation of flavivirus cross-protective immunity. Am J Trop Med Hyg (2011) 0.91
Viral diseases of the central nervous system. Curr Opin Virol (2015) 0.87
The role of viral persistence in flavivirus biology. Pathog Dis (2014) 0.86
The involvement of microglial cells in Japanese encephalitis infections. Clin Dev Immunol (2012) 0.85
Acute flaccid myelitis: A clinical review of US cases 2012-2015. Ann Neurol (2016) 0.83
Acute transverse myelitis (ascending myelitis) as the initial manifestation of Japanese encephalitis: a rare presentation. Case Rep Infect Dis (2013) 0.82
Zika Virus Infection as a Cause of Congenital Brain Abnormalities and Guillain-Barré Syndrome: Systematic Review. PLoS Med (2017) 0.81
Neurologic aspects of infections in international travelers. Neurologist (2005) 0.77
NEUROLOGICAL INFECTIONS IN THE RETURNING INTERNATIONAL TRAVELER. Continuum (Minneap Minn) (2006) 0.76
Development and application of an antigen capture ELISA assay for diagnosis of Japanese encephalitis virus in swine, human and mosquito. Virol J (2012) 0.76
Visualization of a neurotropic flavivirus infection in mouse reveals unique viscerotropism controlled by host type I interferon signaling. Theranostics (2017) 0.75
Post-dengue parkinsonism. BMC Infect Dis (2013) 0.75
Japanese encephalitis virus and poliomyelitis-like illness. Lancet (1998) 0.75
Entomological investigations into an epidemic of Japanese encephalitis (JE) in northern districts of West Bengal, India (2011-2012). Indian J Med Res (2014) 0.75
Prolonged Motor Weakness With Syringomyelia in Japanese Encephalitis: A Case Study. Ann Rehabil Med (2015) 0.75
Etiological profile of noncompressive myelopathies in a tertiary care hospital of Northeast India. Ann Indian Acad Neurol (2017) 0.75
Bilateral facial palsy as a manifestation of Japanese encephalitis. BMJ Case Rep (2012) 0.75
Emerging and reemerging neurologic infections. Neurohospitalist (2014) 0.75
Tropical Diseases on Insurgence: Clinician's Perspective. Indian J Dermatol (2017) 0.75
Multilocus sequence typing for characterization of methicillin-resistant and methicillin-susceptible clones of Staphylococcus aureus. J Clin Microbiol (2000) 34.08
Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. J Infect Dis (2000) 11.44
An enzyme-linked immunosorbent assay to characterize dengue infections where dengue and Japanese encephalitis co-circulate. Am J Trop Med Hyg (1989) 10.52
A prospective study of dengue infections in Bangkok. Am J Trop Med Hyg (1988) 8.54
Melioidosis: a major cause of community-acquired septicemia in northeastern Thailand. J Infect Dis (1989) 8.24
Recombination within natural populations of pathogenic bacteria: short-term empirical estimates and long-term phylogenetic consequences. Proc Natl Acad Sci U S A (2001) 7.90
Effects of artemisinin derivatives on malaria transmissibility. Lancet (1996) 7.42
Human cerebral malaria. A quantitative ultrastructural analysis of parasitized erythrocyte sequestration. Am J Pathol (1985) 7.14
Effects of artesunate-mefloquine combination on incidence of Plasmodium falciparum malaria and mefloquine resistance in western Thailand: a prospective study. Lancet (2000) 7.06
A plaque reduction test for dengue virus neutralizing antibodies. J Immunol (1967) 5.78
Neurological manifestations of dengue infection. Lancet (2000) 5.69
Effect of temperature on the vector efficiency of Aedes aegypti for dengue 2 virus. Am J Trop Med Hyg (1987) 5.53
The epidemiology of malaria in a Karen population on the western border of Thailand. Trans R Soc Trop Med Hyg (1996) 5.35
Qinghaosu. Lancet (1993) 5.25
Dengue in the early febrile phase: viremia and antibody responses. J Infect Dis (1997) 5.13
Halofantrine versus mefloquine in treatment of multidrug-resistant falciparum malaria. Lancet (1993) 5.11
Early clinical and laboratory indicators of acute dengue illness. J Infect Dis (1997) 5.00
Plasmodium falciparum: in vitro studies of the pharmacodynamic properties of drugs used for the treatment of severe malaria. Exp Parasitol (1993) 4.98
Randomised double-blind placebo-controlled trial of SPf66 malaria vaccine in children in northwestern Thailand. Shoklo SPf66 Malaria Vaccine Trial Group. Lancet (1996) 4.90
Origins of dengue type 2 viruses associated with increased pathogenicity in the Americas. Virology (1997) 4.88
Antibody-dependent enhancement of dengue virus growth in human monocytes as a risk factor for dengue hemorrhagic fever. Am J Trop Med Hyg (1989) 4.79
Pharmacokinetics and pharmacodynamics of lumefantrine (benflumetol) in acute falciparum malaria. Antimicrob Agents Chemother (2000) 4.77
Etiology of interepidemic periods of mosquito-borne disease. Proc Natl Acad Sci U S A (2000) 4.75
Evidence that maternal dengue antibodies are important in the development of dengue hemorrhagic fever in infants. Am J Trop Med Hyg (1988) 4.65
A controlled trial of artemether or quinine in Vietnamese adults with severe falciparum malaria. N Engl J Med (1996) 4.64
The pfmdr1 gene is associated with a multidrug-resistant phenotype in Plasmodium falciparum from the western border of Thailand. Antimicrob Agents Chemother (1999) 4.64
Plasmodium falciparum antimalarial drug susceptibility on the north-western border of Thailand during five years of extensive use of artesunate-mefloquine. Trans R Soc Trop Med Hyg (2000) 4.63
Quinolone-resistant Salmonella typhi in Viet Nam: molecular basis of resistance and clinical response to treatment. Clin Infect Dis (1997) 4.53
The epidemiology of severe malaria in an area of low transmission in Thailand. Trans R Soc Trop Med Hyg (1997) 4.48
Pre-referral rectal artesunate to prevent death and disability in severe malaria: a placebo-controlled trial. Lancet (2008) 4.35
Fake antimalarials in Southeast Asia are a major impediment to malaria control: multinational cross-sectional survey on the prevalence of fake antimalarials. Trop Med Int Health (2004) 4.35
Dengue virus structural differences that correlate with pathogenesis. J Virol (1999) 4.26
Treatment of multidrug-resistant Plasmodium falciparum malaria with 3-day artesunate-mefloquine combination. J Infect Dis (1994) 4.17
Fake artesunate in southeast Asia. Lancet (2001) 3.84
Mefloquine-resistant falciparum malaria on the Thai-Burmese border. Lancet (1991) 3.72
A quantitative analysis of the microvascular sequestration of malaria parasites in the human brain. Am J Pathol (1999) 3.72
Diagnosis of adult tuberculous meningitis by use of clinical and laboratory features. Lancet (2002) 3.65
Effects of Plasmodium vivax malaria in pregnancy. Lancet (1999) 3.62
Identification of Pseudomonas pseudomallei in clinical practice: use of simple screening tests and API 20NE. J Clin Pathol (1989) 3.57
Therapeutic responses to different antimalarial drugs in vivax malaria. Antimicrob Agents Chemother (2000) 3.46
Factors contributing to anemia after uncomplicated falciparum malaria. Am J Trop Med Hyg (2001) 3.46
Antibody capture immunoassay detection of japanese encephalitis virus immunoglobulin m and g antibodies in cerebrospinal fluid. J Clin Microbiol (1982) 3.44
Artesunate/mefloquine treatment of multi-drug resistant falciparum malaria. Trans R Soc Trop Med Hyg (1998) 3.39
Persistence of Plasmodium falciparum HRP-2 in successfully treated acute falciparum malaria. Trans R Soc Trop Med Hyg (2001) 3.32
Cardiac effects of antimalarial treatment with halofantrine. Lancet (1993) 3.32
The epidemiology of melioidosis in Ubon Ratchatani, northeast Thailand. Int J Epidemiol (1994) 3.23
Neurological sequelae of cerebral malaria in children. Lancet (1990) 3.11
Rapid serologic diagnosis of dengue virus infection using a commercial capture ELISA that distinguishes primary and secondary infections. Am J Trop Med Hyg (1999) 3.11
Malaria during pregnancy in an area of unstable endemicity. Trans R Soc Trop Med Hyg (1992) 3.10
Severe hypoglycemia and hyperinsulinemia in falciparum malaria. N Engl J Med (1983) 3.07
Clinical pharmacokinetics of antimalarial drugs. Clin Pharmacokinet (1985) 3.03
Quantitation of bacteria in blood of typhoid fever patients and relationship between counts and clinical features, transmissibility, and antibiotic resistance. J Clin Microbiol (1998) 3.02
Efficacy of six doses of artemether-lumefantrine (benflumetol) in multidrug-resistant Plasmodium falciparum malaria. Am J Trop Med Hyg (1999) 2.98
Early immune activation in acute dengue illness is related to development of plasma leakage and disease severity. J Infect Dis (1999) 2.96
Risk factors for gametocyte carriage in uncomplicated falciparum malaria. Am J Trop Med Hyg (1999) 2.94
Relation of the stage of parasite development in the peripheral blood to prognosis in severe falciparum malaria. Trans R Soc Trop Med Hyg (1993) 2.90
Molecular basis of sequestration in severe and uncomplicated Plasmodium falciparum malaria: differential adhesion of infected erythrocytes to CD36 and ICAM-1. J Infect Dis (1991) 2.87
Direct in vivo assessment of microcirculatory dysfunction in severe falciparum malaria. J Infect Dis (2008) 2.77
Artemether-lumefantrine for the treatment of multidrug-resistant falciparum malaria. Trans R Soc Trop Med Hyg (2000) 2.76
Japanese encephalitis. J Neurol Neurosurg Psychiatry (2000) 2.76
Arabinose assimilation defines a nonvirulent biotype of Burkholderia pseudomallei. Infect Immun (1997) 2.72
Quinine pharmacokinetics and toxicity in cerebral and uncomplicated Falciparum malaria. Am J Med (1982) 2.71
Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3'-untranslated region. Am J Trop Med Hyg (2001) 2.67
Population dynamics of untreated Plasmodium falciparum malaria within the adult human host during the expansion phase of the infection. Parasitology (2002) 2.67
Adverse effects of falciparum and vivax malaria and the safety of antimalarial treatment in early pregnancy: a population-based study. Lancet Infect Dis (2011) 2.65
Randomized comparison of artemether-benflumetol and artesunate-mefloquine in treatment of multidrug-resistant falciparum malaria. Antimicrob Agents Chemother (1998) 2.61
Relapse in melioidosis: incidence and risk factors. J Infect Dis (1993) 2.61
Kinetics of IgM and IgG responses to Japanese encephalitis virus in human serum and cerebrospinal fluid. J Infect Dis (1985) 2.59
Antimalarial drugs reduce cytoadherence and rosetting Plasmodium falciparum. J Infect Dis (1996) 2.59
Clinical features cannot predict a diagnosis of malaria or differentiate the infecting species in children living in an area of low transmission. Trans R Soc Trop Med Hyg (1998) 2.54
Quantitative recovery of Burkholderia pseudomallei from soil in Thailand. Trans R Soc Trop Med Hyg (1996) 2.54
Mefloquine pharmacokinetic-pharmacodynamic models: implications for dosing and resistance. Antimicrob Agents Chemother (2000) 2.54
Quantitation of bacteria in bone marrow from patients with typhoid fever: relationship between counts and clinical features. J Clin Microbiol (2001) 2.53
Extinction and rapid emergence of strains of dengue 3 virus during an interepidemic period. Virology (2002) 2.53
High rate of Plasmodium vivax relapse following treatment of falciparum malaria in Thailand. Lancet (1987) 2.52
Evaluation of a rapid immunochromatographic test for diagnosis of dengue virus infection. J Clin Microbiol (1998) 2.50
The prognostic and pathophysiologic role of pro- and antiinflammatory cytokines in severe malaria. J Infect Dis (1999) 2.49
Dengue virus identification by the plaque reduction neutralization test. J Immunol (1967) 2.45
The antimicrobial susceptibility of Pseudomonas pseudomallei. Emergence of resistance in vitro and during treatment. J Antimicrob Chemother (1989) 2.44
Microsatellite variation, repeat array length, and population history of Plasmodium vivax. Mol Biol Evol (2006) 2.43
The pathophysiologic and prognostic significance of acidosis in severe adult malaria. Crit Care Med (2000) 2.42
The effects of dopamine and adrenaline infusions on acid-base balance and systemic haemodynamics in severe infection. Lancet (1996) 2.41
Association of genetic mutations in Plasmodium vivax dhfr with resistance to sulfadoxine-pyrimethamine: geographical and clinical correlates. Antimicrob Agents Chemother (2001) 2.40
The use of selective media for the isolation of Pseudomonas pseudomallei in clinical practice. J Med Microbiol (1990) 2.39
Activation of T lymphocytes in dengue virus infections. High levels of soluble interleukin 2 receptor, soluble CD4, soluble CD8, interleukin 2, and interferon-gamma in sera of children with dengue. J Clin Invest (1991) 2.37